Key Takeaways:
(Bloomberg) -- Akari Therapeutics (Nasdaq: AKTX) saw its shares surge after announcing positive preclinical data for its lead TROP2-targeting antibody-drug conjugate (ADC), AKTX-101, which demonstrated superior potency in tumor models through a novel payload targeting the RNA spliceosome. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting, supports the advancement of AKTX-101 into Phase 1 studies.
"The differentiated cytotoxicity of AKTX-101 is a direct result of our novel payload's mechanism of action," an Akari spokesperson said. "By targeting the RNA spliceosome, we have the potential to address the resistance that often develops with Topoisomerase I inhibitors, a common payload in other TROP2 ADCs."
The preclinical studies compared AKTX-101 against leading TROP2 ADCs across various tumor models, including bladder, lung, and breast cancer. In these models, AKTX-101 consistently showed superior potency. The company's unique PH1 payload, a modulator of the RNA spliceosome, represents a first-in-class approach within the TROP2 ADC space.
This development positions Akari as a contender in the rapidly evolving TROP2 ADC market, which is projected to become a $12 billion opportunity by 2033. The company's novel approach may offer a significant advantage in a field currently dominated by drugs with Topoisomerase I inhibitor payloads. The positive data is a critical step for Akari, a clinical-stage biotechnology company, as it prepares to move AKTX-101 into human trials.
This article is for informational purposes only and does not constitute investment advice.
